Allogeneic Immunotherapy for Malignant Diseases - J. Barrett, Y. Jiang (Marcel Dekker, 2000) WW

404 Pages·2000·52.44 MB·English

N:

This book is printed on acid-free paper.

e a ~ ~ ~ a r t e r s
Marcel Dekker, Inc.
270 Madison Avenue, New York, NY
l0016
tel: [phone]: fax: [phone]

Marcel Dekker AG
Wutgasse 4, Postfach 8 12, CH-4001 Basel, Switzerland
tel: [phone]; fax: 4 1-6
-26 -8896

http://www.dekker.com

The publisher offers discounts on this book when ordered
in bulk quantities. For more
information, write to Special Sales/Professional Marketing at the headquarters address
above.

Neither this book nor any part may be reproduced or transmitted in any form
by any
means, electronic or mechanical, including photocopying,
nlicro~lming, and recording,
by any information storage and retrieval system, without permission in writing
From
the publisher.

Current printing (last digit):
I 0 9 8 7 6 5 4 3 2 1

all our patients,
whose bravery in adversity is an inspiration for us
to improve our understanding of disease processes
and devise better ways to treat and cure.

This Page Intentionally Left Blank

The current volume, Allogeneic Il~ll~lull~)theru~~
,for ~ u ~ i g ~ ~ u l ~ t
Diseases, is the
twenty-second in the Basic and Clinical Oncology series. Many of the advances
in oncology have resulted from close interaction between the basic scientist and
the clinical researcher. The current volume illustrates the success of this relation-
ship
demonstrated by new insights into clinical drug resistance and means of
circumventing this potential obstacle to effective cancer treatment.
editor of the series, my goal is to recruit volume editors who not only
have established reputations based on their outstanding contributions to oncology,
but who also have an appreciation for the dynamic interface between the labora-
tory and the clinic.
date, the series has consisted of monographs on topics that
are of a high level of current interest. Allogeneic Il~~lnulz~tlleru~~y
jbr ~ ~ ~ l i ~ l ~ ~ ~ l l t
Diseases certainly fits into this category and is a most important addition to the
series.
Volumes in progress focus on tumor angiogenesis and microcirculation,
and cancer in the elderly.
anticipate that these books will provide
valuable
contribution to the oncology literature.

Bruce D. Chesorz

This Page Intentionally Left Blank

Allogeneic stem-cell transplantation is becoming an essential component of clini-
cal hematology and oncology practice. The curative effect
of allogeneic stem cell
transplantation
attributed at least partially to an allogeneic immune response:
the graft-versus-leukelnia (GVL) or graft-versus-tumor (GVT) effect. For the last
decade or so, our perception of the GVL phenomenon has changed dramatically.
We observed in the 1nid-’80s that depletion
of
cells from the graft dramatically
increased the rate of leukemia relapse; subsequently it became evident that remis-
sions could be reinduced
by donor lymphocyte transfusions to patients
with leuke-
mia relapsing after bone marrow transplantation. Although variable
in its expres-
sion, the allogeneic GVT effect appears to extend to a
variety of acute and chronic
myeloid and lymphoid malignancies and possibly solid tumors. With
new insights
into the cellular and molecular biology
of GVL, we have advanced from the stage
of trying to prove the existence of a GVL effect to understanding it better and
applying it more effectively.
Anyone reading current publications on bone marrow transplantation will
have noticed a growing number of original papers and review articles on
GVL
which signal an increased awareness and demand for information
the topic.
Alongside the applied research in GVL, there are continuing advances in cellular
immunology and tumor immunology that improve our understanding of the
response to l~alignancies, Looking forward
to the next decade, the use of alloge-
neic cells promises important therapeutic benefits for our patients. In this book,
authors who are leaders in their respective fields provide a comprehensive review
of the GVLlGVT effect, from descriptions of the alloimmune responses to the

vii

clinical applicatio~s of
We hope this book will bring to its readership state-
of-the-art knowledge on the subject and
indicate directions for future re-
search and therapeutic applications in GVL.

To my parents for their diligent work to support
me through my education; to
my wife, Junhua, for her sacrifice to free me to pursue my career.

Y-Z J

Introduction: The Graft-Versus-Leukemia Effect

2.

3.

4.

The Immune Response to Alloantigens
Lord
Robert I. Leclzler

Experinlental Animal Models in the Study
GVL Reactions
Robert
Truitt, Robert Ko~llgold, BIyon D.
Robert To~~ll~~elld, md
Bruce R.

Effector Cells and Mechanisms of the GVL Effect
Yirz-Zheng Jiang

Minor Histocol~patibiIity Antigens in GVL
~ L t t i . ~ Ells Coulrny

Tissue-Specific Antigens in GVL
JeRrey

V
vii

13

75

135